Raltegravir with unboosted atazanavir 300 mg twice daily in antiretroviral treatment-experienced participants

Journal of the International Association of Physicians in AIDS Care

Volumn 8, Issue 2, 2009, Pages 87-92

  Gupta, Shaili ^a,c   Lataillade, Max ^a   Farber, Steven ^a,b   Kozal, Michael J ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

antiretroviral resistance; HIV; raltegravir; treatment experienced; unboosted atazanavir

Indexed keywords

2 PYRROLIDONE DERIVATIVE; ATAZANAVIR; OLIGOPEPTIDE; PROTEINASE INHIBITOR; PYRIDINE DERIVATIVE; RALTEGRAVIR; VIRUS RNA;

AGED; ARTICLE; BLOOD; CASE REPORT; CD4 LYMPHOCYTE COUNT; DRUG COMBINATION; DRUG EFFECT; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MIDDLE AGED; PHYSIOLOGY; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

AGED; AGED, 80 AND OVER; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; PYRROLIDINONES; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 66149192679     PISSN: 15451097     EISSN: 15570886     Source Type: Journal    
DOI: 10.1177/1545109709332471     Document Type: Article

References (13)

1. Grinsztejn B., Nguyen B-Y., Katlama C., et al, and Protocol 005 Team. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomized controlled trial. Lancet. 2007 ; 369: 1261-1269. (Pubitemid 46553846)
2. Murray JM, Emery S., Kelleher AD, et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS. 2007 ; 21: 2315-2321. (Pubitemid 350287458)
3. Markowitz M., Nguyen BY, Gotuzzo E., et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007 ; 46: 125-133. (Pubitemid 47482607)
4. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analysis of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008 ; 359: 355-365.
5. Iwamoto M., Wenning LA, Mistry GC, et al. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin Infect Dis. 2008 ; 47: 137-140. (Pubitemid 351920602)
6. DHHS Guidelines for Use of Antiretroviral Agents in HIV-1-Infected Adults and Adoloescents. Available at: http://aidsinfo.nih.gov/contentfiles/ AdultandAdolescentGLpdf. Accessed October 10, 2008.
7. Malan DR, Krantz E., Wirtz V., David N., Hammond J., McGrath D., and 089 Study Group. Efficacy and safety of atazanavir, with or without ritonavir, as part of once daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr. 2008 ; 47: 161-167. (Pubitemid 351172182)
8. Zhu L., Mahnke L., Persson A., et al. Pharmacokinetics, safety and tolerability of atazanavir 200, 300, and 400 mg twice daily in healthy subjects Abstract A-952 presented at 48th ICAAC/IDSA 46th annual meeting; October 25-28, 2008 ; Washington, DC.
9. Johnson V., Brun-Vezinet F., Clotet B., et al. Update of the drug resistance mutations in HIV-1: spring 2008. IAS-USA Top HIV Med. 2008 ; 16: 62-67. Available at: http://www.iasusa.org/resistance-mutations
10. Stanford University HIV Drug Resistance Database. Available at: http://hivdb.stanford.edu. Accessed October 10, 2008.
11. Anderson JA, Jiang H., Ding X., et al and AIDS Clinical Trials Group Study 359 Protocol Team. Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection. AIDS Res Hum Retroviruses. 2008 ; 24: 685-694. (Pubitemid 351748774)
12. Markowitz M., Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naïve HIV-1 infected individuals. J Acquir Immune Defic Syndr. 2006 ; 43: 509-515. (Pubitemid 44885615)
13. Haas DW, Zala C., Schrader S., et al and Protocol AI424-009 Study Group. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized Comparative Pilot Trial. AIDS. 2003 ; 17: 1339-1350.